Monte Rosa Therapeutics, Inc. (GLUE) is a pioneering biopharmaceutical company based in Boston, Massachusetts, focused on developing precision small molecule therapeutics that leverage natural cellular processes for targeted protein degradation. The company employs its proprietary technology platforms to tackle substantial unmet medical needs, with a primary focus on oncology and autoimmune disorders, demonstrated through its robust pipeline of innovative drug candidates. Committed to scientific excellence and advancing treatment paradigms, Monte Rosa is well-positioned to enhance patient outcomes and lead transformative change in the pharmaceutical industry. Show more
Location: 321 HARRISON AVENUE, BOSTON, MA, UNITED STATES, 02118, Boston, MA, 02118, USA | Website: https://www.monterosatx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
1.565B
52 Wk Range
$3.50 - $25.77
Previous Close
$21.36
Open
$21.03
Volume
1,532,407
Day Range
$19.91 - $21.36
Enterprise Value
985.1M
Cash
208.3M
Avg Qtr Burn
N/A
Insider Ownership
0.81%
Institutional Own.
93.93%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
MRT-6160 Details Inflammatory disease, Autoimmune disease, Neurological disorder | Phase 2 Initiation | |
MRT-2359 Details Solid tumor/s, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
MRT-8102 Details Inflammatory disease | Phase 1 Data readout |
